×
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
NYSE:RDY

Dr. Reddy's Laboratories Stock Forecast, Price & News

$55.84
+0.45 (+0.81%)
(As of 07/1/2022 08:45 PM ET)
Add
Compare
Today's Range
$55.01
$55.87
50-Day Range
$49.62
$56.48
52-Week Range
$47.88
$75.50
Volume
85,400 shs
Average Volume
193,712 shs
Market Capitalization
$9.29 billion
P/E Ratio
29.39
Dividend Yield
0.50%
Price Target
$66.71

Dr. Reddy's Laboratories MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
19.5% Upside
$66.71 Price Target
Short Interest
Healthy
1.06% of Shares Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
27.49%
From $2.51 to $3.20 Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.69 out of 5 stars

Medical Sector

851st out of 1,412 stocks

Pharmaceutical Preparations Industry

423rd out of 673 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive RDY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dr. Reddy's Laboratories and its competitors with MarketBeat's FREE daily newsletter.

Dr. Reddy

About Dr. Reddy's Laboratories (NYSE:RDY) Stock

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the research, development, and commercialization of differentiated formulations for dermatology and neurology therapeutic areas. The Others segment engages in developing therapies in the fields of oncology and inflammation. As of March 31, 2021, it had three late stage projects at various stages of development. Its therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

RDY Stock News Headlines

Dr Reddy's Laboratories Ltd ADR RDY
Here's what Wall Street expects from Dr Reddys Laboratories's earnings
Dr. Reddy's FQ3 2022 Earnings Preview
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
22,739
Year Founded
1984

Company Calendar

Last Earnings
10/29/2021
Today
7/03/2022
Next Earnings (Estimated)
7/26/2022
Fiscal Year End
3/31/2023

Price Target and Rating

Average Stock Price Forecast
$66.71
High Stock Price Forecast
$70.00
Low Stock Price Forecast
$63.41
Forecasted Upside/Downside
+19.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.5
Research Coverage
2 Analysts

Profitability

Net Income
$315.81 million
Pretax Margin
15.07%

Debt

Sales & Book Value

Annual Sales
$2.83 billion
Cash Flow
$3.28 per share
Book Value
$15.34 per share

Miscellaneous

Free Float
163,097,000
Market Cap
$9.29 billion
Optionable
Optionable
Beta
0.52

Social Links















Dr. Reddy's Laboratories Frequently Asked Questions

Should I buy or sell Dr. Reddy's Laboratories stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dr. Reddy's Laboratories in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" Dr. Reddy's Laboratories stock.
View analyst ratings for Dr. Reddy's Laboratories
or view top-rated stocks.

What is Dr. Reddy's Laboratories' stock price forecast for 2022?

2 Wall Street research analysts have issued 1 year target prices for Dr. Reddy's Laboratories' stock. Their RDY stock forecasts range from $63.41 to $70.00. On average, they anticipate Dr. Reddy's Laboratories' stock price to reach $66.71 in the next year. This suggests a possible upside of 19.5% from the stock's current price.
View analysts' price targets for Dr. Reddy's Laboratories
or view top-rated stocks among Wall Street analysts.

How has Dr. Reddy's Laboratories' stock price performed in 2022?

Dr. Reddy's Laboratories' stock was trading at $65.41 at the beginning of 2022. Since then, RDY stock has decreased by 14.6% and is now trading at $55.84.
View the best growth stocks for 2022 here
.

When is Dr. Reddy's Laboratories' next earnings date?

Dr. Reddy's Laboratories is scheduled to release its next quarterly earnings announcement on Tuesday, July 26th 2022.
View our earnings forecast for Dr. Reddy's Laboratories
.

How were Dr. Reddy's Laboratories' earnings last quarter?

Dr. Reddy's Laboratories Limited (NYSE:RDY) issued its earnings results on Friday, October, 29th. The company reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.56 by $0.24. The business had revenue of $777 million for the quarter. Dr. Reddy's Laboratories had a trailing twelve-month return on equity of 15.94% and a net margin of 11.08%.
View Dr. Reddy's Laboratories' earnings history
.

Is Dr. Reddy's Laboratories a good dividend stock?

Dr. Reddy's Laboratories(NYSE:RDY) pays an annual dividend of $0.28 per share and currently has a dividend yield of 0.50%. The dividend payout ratio of Dr. Reddy's Laboratories is 14.74%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Dr. Reddy's Laboratories will have a dividend payout ratio of 8.75% next year. This indicates that Dr. Reddy's Laboratories will be able to sustain or increase its dividend.
View Dr. Reddy's Laboratories' dividend history.

Who are Dr. Reddy's Laboratories' key executives?

Dr. Reddy's Laboratories' management team includes the following people:
  • Mr. Gunupati Venkateswara Prasad B.E., Co-Chairman, MD & Member of Management Council (Age 62, Pay $2M)
  • Mr. Kallam Satish Reddy, Chairman & Member of the Management Council (Age 55, Pay $1.35M)
  • Mr. Erez Israeli M.B.A., CEO & Member of the Management Council (Age 54)
  • Mr. Parag Agarwal, CFO & Member of Management Council
  • Mr. Deepak Sapra M.B.A., CEO of API & Services & Member of Management Council (Age 47)
  • Mr. Venkata Ramana Motupalli M.B.A., MBA, CEO of Branded Markets - India & Emerging Countries and Member of Management Council (Age 53)
  • Ms. Archana Bhaskar B.Sc., M.B.A., EVP, Head of Corp. Communications, Chief HR Officer & Member of Management Council (Age 55)
  • Mr. Sanjay Sharma B.Tech., Exec. VP, Global Head of Global Manufacturing & Member of Management Council (Age 54)
  • Mr. Marc Kikuchi B.A., M.B.A., CEO of North America Generics & Member of Management Council (Age 53)
  • Mr. Patrick Aghanian B.A., M.B.A., CEO of European Generics & Member of Management Council (Age 57)

What is G. V. Prasad's approval rating as Dr. Reddy's Laboratories' CEO?

528 employees have rated Dr. Reddy's Laboratories CEO G. V. Prasad on Glassdoor.com. G. V. Prasad has an approval rating of 96% among Dr. Reddy's Laboratories' employees. This puts G. V. Prasad in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Dr. Reddy's Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dr. Reddy's Laboratories investors own include Siemens Aktiengesellschaft (SIEGY), Tata Motors (TTM), Infosys (INFY), Vedanta (VEDL), HDFC Bank (HDB), Alibaba Group (BABA), GSK (GSK), Merck & Co., Inc. (MRK), NVIDIA (NVDA) and Pfizer (PFE).

What is Dr. Reddy's Laboratories' stock symbol?

Dr. Reddy's Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "RDY."

How do I buy shares of Dr. Reddy's Laboratories?

Shares of RDY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Dr. Reddy's Laboratories' stock price today?

One share of RDY stock can currently be purchased for approximately $55.84.

How much money does Dr. Reddy's Laboratories make?

Dr. Reddy's Laboratories (NYSE:RDY) has a market capitalization of $9.29 billion and generates $2.83 billion in revenue each year. The company earns $315.81 million in net income (profit) each year or $1.90 on an earnings per share basis.

How many employees does Dr. Reddy's Laboratories have?

Dr. Reddy's Laboratories employs 22,739 workers across the globe.

When was Dr. Reddy's Laboratories founded?

Dr. Reddy's Laboratories was founded in 1984.

How can I contact Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories' mailing address is 8-2-337 ROAD NO.3 BANJARA HILLS, HYDERABAD K7, 500-034. The official website for Dr. Reddy's Laboratories is www.drreddys.com. The company can be reached via phone at 914049002900, via email at amita@drreddys.com, or via fax at 91-40-4900-2999.

This page (NYSE:RDY) was last updated on 7/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.